TABLE 2.
Clinical characteristic |
Intermittent-dosing regimen |
Continuous-dosing regimen |
||||||
---|---|---|---|---|---|---|---|---|
PNAb (days) | bBW (g)c | cBW (kg)d | Loading dose (mg/kg)e,f | Maintenance dose (mg/kg/day) (no. of doses)f | AUC24 (mg · h/liter)g |
Loading dose (mg/kg) | Maintenance dose (mg/kg/day)h | AUC24 (mg · h/liter) |
0–7 | ≤700 | 16 | 15 (3) | 264–301 | 10.5 | 25 | 440–502 | |
700–1,000 | 21 (3) | 332–450 | 25 | 395–536 | ||||
1,000–1,500 | 27 (3) | 349–490 | 27 | 349–484 | ||||
1,500–2,500 | 30 (4) | 339–530 | 30 | 339–530 | ||||
>2,500 | 36 (4) | 354–482 | 36 | 354–482 | ||||
8–14 | ≤700 | 20 | 21 (3) | 331–590 | 10.5 | 25 | 394–703 | |
700–1,000 | 27 (3) | 341–475 | 32 | 404–563 | ||||
1,000–1,500 | 36 (3) | 390–610 | 36 | 390–610 | ||||
1,500–2,500 | 40 (4) | 380–504 | 40 | 380–504 | ||||
>2,500 | 48 (4) | 390–633 | 48 | 390–633 | ||||
14–28 | ≤700 | 23i | 24 (3) | 337–444 | 10.5 | 30 | 421–556 | |
700–1,000 | 42 (3) | 407–610 | 42 | 407–610 | ||||
1,000–1,500 | 45 (3) | 385–571 | 45 | 385–571 | ||||
1,500–2,500 | 52 (4) | 311–657 | 52 | 311–657 | ||||
>2,500 | 60 (4) | 357–572 | 60 | 357–572 | ||||
>28 | <2.5 | 18 | 32 (4) | 385–471 | 13 | 32 | 385–471 | |
2.5–5.0 | 24 | 40 (4) | 385–468 | 40 | 385–468 | |||
5.0–10.0 | 27 | 52 (4) | 434–500 | 52 | 434–500 | |||
>10.0 | 30 | 60 (4) | 463–502 | 60 | 463–502 |
This dosing algorithm (mg/kg current bodyweight) is based on a target AUC24/MIC of >400.
PNA, postnatal age.
bBW: birth body weight.
cBW, current body weight.
The maximum loading dose is 1,200 mg.
If ibuprofen is given and PNA is <28 days, decrease the dose by 2 mg/kg/dose.
AUC24 is the noncompartmental calculated area under the concentration-time curve over 24 h. Values are the expected daily AUC range for the different dosing groups.
If ibuprofen is given and the PNA is <28 days, decrease the maintenance dose by 6 mg/kg/day.
The loading dose is 26 mg/kg if the PNA is 21 to 28 days.